MHRA: An innovative approach to developing malaria vaccine

The Medicines and Healthcare products Regulatory Agency (MHRA) has today published its fourth case study detailing how the regulator has helped researchers at the Jenner Institute, University of Oxford take a step closer to developing an effective vaccine against the global killer Malaria. Through engagement with the University of Oxford our Innovation Office has helped contribute to the development of a viral vector, which is used as a carrier of genetic material to help treat a specific disease.